TrialAIDS research and therapy2016

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients.

Hongwei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.